.Pharmacolibrary.Drugs.ATC.L.L01XX57

Information

name:Plitidepsin
ATC code:L01XX57
route:intravenous
compartments:3
dosage:5.0mg
volume of distribution:500.0L
clearance:45.0L/h
other parameters in model implementation

Plitidepsin is a cyclic depsipeptide isolated from the marine tunicate Aplidium albicans. The drug exhibits antitumor and antiviral activities by targeting the eukaryotic elongation factor eEF1A, disrupting protein synthesis. Plitidepsin has been approved for the treatment of multiple myeloma in some countries and has been under investigation for its potential use in COVID-19 and other conditions.

Pharmacokinetics

Pharmacokinetics reported for adult patients with relapsed/refractory multiple myeloma following intravenous administration in clinical trials.

References

  1. Nalda-Molina, R, et al., & Perez-Ruixo, JJ (2009). Population pharmacokinetics meta-analysis of plitidepsin (Aplidin) in cancer subjects. Cancer chemotherapy and pharmacology 64(1) 97–108. DOI:10.1007/s00280-008-0841-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/18941750

Revisions


Generated at 2025-08-11T18:21:04Z by OpenModelicaOpenModelica 1.25.1 using GenerateDoc.mos